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Abstract
Background: Pandemic influenza A(H1N1) (pH1N1) was first identified in North America in April 2009. Vaccination against
pH1N1 commenced in the U.S. in October 2009 and continued through January 2010. The objective of this study was to
evaluate the cost-effectiveness of pH1N1 vaccination.
Methodology: A computer simulation model was developed to predict costs and health outcomes for a pH1N1 vaccination
program using inactivated vaccine compared to no vaccination. Probabilities, costs and quality-of-life weights were derived
from emerging primary data on pH1N1 infections in the US, published and unpublished data for seasonal and pH1N1
illnesses, supplemented by expert opinion. The modeled target population included hypothetical cohorts of persons aged 6
months and older stratified by age and risk. The analysis used a one-year time horizon for most endpoints but also includes
longer-term costs and consequences of long-term sequelae deaths. A societal perspective was used. Indirect effects (i.e.,
herd effects) were not included in the primary analysis. The main endpoint was the incremental cost-effectiveness ratio in
dollars per quality-adjusted life year (QALY) gained. Sensitivity analyses were conducted.
Results: For vaccination initiated prior to the outbreak, pH1N1 vaccination was cost-saving for persons 6 months to 64 years
under many assumptions. For those without high risk conditions, incremental cost-effectiveness ratios ranged from $8,000–
$52,000/QALY depending on age and risk status. Results were sensitive to the number of vaccine doses needed, costs of
vaccination, illness rates, and timing of vaccine delivery.
Conclusions: Vaccination for pH1N1 for children and working-age adults is cost-effective compared to other preventive
health interventions under a wide range of scenarios. The economic evidence was consistent with target recommendations
that were in place for pH1N1 vaccination. We also found that the delays in vaccine availability had a substantial impact on
the cost-effectiveness of vaccination.
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Introduction
2009 pandemic influenza (A)H1N1 (pH1N1)was first identified
in Spring 2009 and has continued to circulate in North America
and elsewhere.[1,2,3,4,5] Initial doses of a vaccine to prevent
pH1N1 infection first became available starting in early October
2009. At that time, target groups for vaccination were identified by
the Centers for Disease Control and Prevention’s Advisory
Committee for Immunization Practices (ACIP).[6] Targeted age
groups differ considerably than those for seasonal influenza
vaccine for people 65 years and older. Supply of the pH1N1
vaccine was anticipated to be limited initially, raising questions of
prioritization. Consideration of the economic consequences of a
vaccination program for pH1N1 can aid decision makers in
vaccine allocation decisions by providing information on the
relative cost-effectiveness of vaccinating specific age and risk
groups.
Most studies using dynamic models suggest that vaccinating
school-aged children preferentially over other age groups is the
optimal strategy for reducing the health consequences of a future
pandemic [7,8,9], although one study supports the ACIP priori-
tization strategy of vaccinating high-risk individuals first.[10] The
approach of preferentially vaccinating schoolchildren, however,
assumes sufficient vaccine is available for all schoolchildren and
that coverage rates among this target group will be high enough to
reach coverage levels that would achieve herd effects. Such an
approach also makes the assumption that society is willing to
accept health risks of vaccine adverse events for school-aged
children in return for health benefits to adults and younger
children. Given the likelihood that vaccine coverage levels may not
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22308be sufficient to achieve herd effects and acknowledging that parent
preferences may not favor vaccinating school-aged children as a
strategy for protecting other individuals but may favor vaccination
of children to prevent illness in their own children, the current
study evaluates the cost-effectiveness of pH1N1 vaccination by
measuring the health benefits that accrue to the vaccinated
individual and does not consider indirect effects of vaccination.
Methods
We used a decision analytic model, built using standard software
(TreeAge Pro 2009 Software, release 1.0, Treeage Software,
Williamstown, MA), to estimate costs and health outcomes for
pH1N1 influenza vaccination compared to no vaccination. A
simplified schematic of the decision model is shown in Figure 1.
Input parameters were derived from emerging data available for
pH1N1 influenza illness in the US in spring/summer 2009,
published data, and expert opinion and are described in more
detail below (Tables 1, 2) and in supplemental materials (Tables S1,
S2). We used a time frame of one year because most costs and
consequences related to influenza occur during a single influenza
season. However, two key outcomes with longer-term effects,
influenza-relateddeathsand long-termsequelae ofinfluenza-related
illness, were included. The analysis used a societal perspective.
Target population
The model includes cohorts of children and adults aged 6
months and older stratified by age and risk of complications. Age
groups were: 6–23 month, 24–35 month (2 yrs), 3–4 years, 5–11
years, 12–17 years, 18–49 years, 50–64 years, and 65 years and
older. Each age group was then divided into two risk-based
groups, higher risk and lower risk, except for age 65 years and
older who are all assumed to be at higher risk for complications.
Higher risk groups were defined using conditions identified by
CDC as placing individuals at higher risk for medical complica-
tions of influenza illness.[6]
Natural history of influenza
Probabilities of hospitalization and death following pH1N1
illness were derived from emerging data for pH1N1 in spring/
summer 2009.[11](Table 1) Input values for probabilities of other
influenza-related outcomes were based on previously established
estimates for seasonal influenza, such as probability of seeking
medical attention during an episode of influenza illness, other
complications treated on an outpatient setting, and long-term
sequelae following hospitalization.[12,13] The range of possible
values for probability of pH1N1 influenza illness during a single
season was varied from 5% to 30% to reflect the limited data on
Figure 1. Simplified representation of simulation model. Systemic reaction = fever and flu-like symptoms for 24 hours following vaccination.
doi:10.1371/journal.pone.0022308.g001
H1N1 Vaccination
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22308possible overall pH1N1 illness attack rates with intermediate
probabilities of 7.6%, 15%, and 21%. One intermediate
probability, 21%, represents the most recent estimate for the
pH1N1 pandemic derived from Shrestha et al (2011).[14] The
probability of 7.6% represents an average non-pandemic influenza
season.
Table 1. Probabilities of H1N1 influenza illnesses, hospitalizations, and deaths by age and risk status.
Age Group Overall Attack Rate Source
5% 7.6% 15% 21% 30%
pH1N1 Influenza Illness Rate [11]
6–23 months 0.0924 0.1405 0.2772 0.3929 0.5544
2 y 0.0924 0.1405 0.2772 0.3929 0.5544
3–4 y 0.0924 0.1405 0.2772 0.3929 0.5544
5–11 y 0.1085 0.1649 0.3254 0.4613 0.6509
12–17 y 0.1085 0.1649 0.3254 0.4613 0.6509
18–49 y 0.0460 0.0699 0.1380 0.1956 0.2760
50–64 y 0.0158 0.0240 0.0474 0.0671 0.0947
$65 y 0.0053 0.0080 0.0159 0.0225 0.0317
Incidence of hospitalizations for pneumonia or other respiratory conditions due to pH1N1 influenza per 100,000 [11,12,13]
1
6–23 months, LR 95.22 141.45 261.41 424.58 459.98
2 y, LR 102.08 151.64 280.25 455.22 493.18
3–4 y, LR 84.63 125.71 232.31 377.28 408.73
5–11 y, LR 33.70 49.84 91.08 151.30 156.92
12–17 y, LR 33.70 49.84 91.08 151.30 156.92
18–49 y, LR 25.60 38.45 73.42 111.43 137.42
50–64 y, LR 13.25 20.04 39.13 56.73 76.39
6–23 months, HR 285.93 424.94 786.28 1279.19 1386.34
2 y, HR 306.55 455.60 843.13 1371.93 1486.91
3–4 y, HR 338.94 503.79 932.48 1517.75 1645.05
5–11 y, HR 202.40 299.39 547.71 911.27 945.26
12–17 y, HR 202.40 299.39 547.71 911.27 945.26
18–49 y, HR 128.07 192.39 367.65 558.41 689.01
50–64 y, HR 66.26 100.26 195.82 283.95 382.55
$65 y, all 14.08 21.23 42.03 59.96 83.16
Incidence of pH1N1 influenza death per 100,000 [11,12,13]
6–23 months, LR 0.0843 0.1252 0.2313 0.3754 0.4066
2 y, LR 0.0904 0.1342 0.2480 0.4024 0.4359
3–4 y, LR 0.0749 0.1113 0.2056 0.3336 0.3614
5–11 y, LR 0.0299 0.0441 0.0807 0.1340 0.1389
12–17 y, LR 0.0299 0.0441 0.0807 0.1340 0.1389
18–49 y, LR 2.8483 4.2772 8.1666 12.3926 15.2811
50–64 y, LR 1.6245 2.4575 4.7975 6.9538 9.3638
6–23 months, HR 0.2530 0.3757 0.6939 1.1262 1.2198
2 y, HR 0.2712 0.4027 0.7439 1.2072 1.3077
3–4 y, HR 0.2998 0.4452 0.8223 1.3346 1.4456
5–11 y, HR 0.1791 0.2649 0.4839 0.8037 0.8336
12–17 y, HR 0.1791 0.2649 0.4839 0.8037 0.8336
18–49 y, HR 14.2422 21.3880 40.8398 61.9785 76.4289
50–64 y, HR 8.1227 12.2882 23.9900 34.7736 46.8276
$65 y, all 1.8141 2.7346 5.4138 7.7222 10.7092
LR = lower-risk; HR = higher-risk.
1Data from seasonal influenza illness was used to estimate the ratio of high risk to low risk based on expert opinion that although the incidence for pH1N1 and seasonal
influenza varied substantially by age, the conditional probability of influenza-related complications for high risk and low risk patients would likely be similar for pH1N1
and seasonal (i.e., within an age group, high risk patients would be more likely to experience influenza-related complications than low-risk patients for both pH1N1 and
seasonal influenza).
doi:10.1371/journal.pone.0022308.t001
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Costs included direct medical costs for influenza events,
including physician visits, over-the-counter and prescription
medications, diagnostic tests, hospitalizations, and long-term
sequelae, based on established costs for seasonal influen-
za.[12,13,15,16] Direct medical costs were adjusted to 2009
dollars using the medical component of the Consumer Price
Index.[17]
Vaccination assumptions
Pandemic H1N1 vaccine effectiveness was assumed to have
similar effectiveness as for seasonal influenza vaccine based on
preliminary studies of 2009 pH1N1 vaccine immunogenicity which
shows immune responses comparable to seasonal influenza
vaccine.[18,19,20,21] Base case (range) vaccine effectiveness was
assumed to be 69% (40%–90%) for individuals aged 6 months to 17
years, 69% (30%–90%) for those 18 to 64 years and 60% (30%–
90%) for those 65 years and older. (Table 2) Vaccination-related
adverse events were assumed to be consistent with rates for seasonal
influenza vaccine. Injection site reactions, systemic reactions,
anaphylaxis, and Guillain Barre ´ syndrome varied by age and are
listed in Table S1. Incidence of Guillain Barre ´ syndrome was based
on data from seasonal influenzavaccine[22]and variedinsensitivity
analyses to reflect rates observed in the 1976 swine flu vaccination
program.[23,24,25,26,27,28,29,30,31,32].
Vaccination-related costs included cost of pH1N1 vaccine
doses, administration fees, and time costs (for parents or patients,
depending on the age of the vaccinee).(Tables 2, S1, S2) We
assumed full vaccination required 2 doses for individuals aged 6
months to 9 years and 1 dose for individuals aged 10 years and
older. Administration costs varied by setting: lower for mass
vaccination clinic and higher for the physician office setting.[33]
For the physician office setting, the proportion of persons
vaccinated at an existing or vaccination-specific visit varied by
age. Assumptions for mid-range costs use data on vaccination
setting by age from seasonal influenza vaccination for adults and
assume a mix of vaccination settings.[34] The proportion of
individuals receiving vaccination in a mass vaccination or
physician office setting varied by age and risk group. Assumptions
for mid-range costs for children also vary by age. 75% of school-
aged children were assumed to be vaccinated in a school-located
setting. Children younger than 5 years were assumed to be
vaccinated in the physician office setting. Costs of adverse events
were based on costs of adverse events associated with inactivated
influenza vaccine.[15] Time costs for vaccination time for adults
and parents of vaccinated children were also included.
Table 2. Effectiveness and costs associated with pH1N1 vaccination by age and risk status (inactivated vaccine).
Vaccine Effectiveness
Age Group Most Likely Minimum Maximum Source
6 mo–17 y 0.690 0.40 0.90 [19]
18–64 y 0.690 0.30 0.90 [18,19]
$65 y 0.600 0.30 0.90 [20,21]
Vaccination Costs
2
Mass Vaccination Setting Mid-Range
3 Physician Office Setting
4 [13,33,58,59]
6–23 months $68.67 - $93.32
2y $68.67 - $93.32
3–4 y $68.67 - $93.32
5–11 y $39.80 $53.18 $93.32
12–17 y $19.90 $25.72 $43.18
18–49 y, LR $34.33 $35.30 $37.89
50–64. LR $34.33 $35.07 $37.06
18–49 y, HR $34.33 $36.11 $37.89
50–64. HR $34.33 $35.97 $37.06
$65 y, all $34.33 $33.05 $31.77
LR = lower-risk; HR = higher-risk.
1
1Individuals were defined to be at higher risk for influenza-related complications due to underlying medical conditions, which include chronic pulmonary and significant
cardiac conditions and other recognized high-risk conditions.[6]
2Total vaccination costs include the cost for the vaccine (1 dose for persons aged 10 years or older and 2 doses for children aged 6 months to 9 years), administration
costs, and time costs as appropriate. Cost of the vaccine dose was based on the contracts negotiated by the Biomedical Advanced Research and Development
Authority for pH1N1 vaccine in 2009 (average cost: $8.60 per dose). Administration costs are assumed to be $11.30 per dose in a mass vaccination and either $13.71 for
administration during an existing visit to a clinician in a physician office setting or $20.92 for administration during an extra physician office setting visit based on
Medicare payment rates.[33] For vaccination cost estimates in the mass vaccination setting, (travel and vaccination) time costs included 12 minutes for waiting and
vaccination time[13] at the clinic and 30 minutes of travel time for all adult age groups and for age groups less than 5 years to account for parent time costs. Children
5–17 years in the mass vaccination setting are assumed to be vaccinated in a school setting and therefore no parent time costs were included.
3Assumes a mix of mass vaccination and physician office. For the mixed setting, the proportion of persons vaccinated in a mass vaccination setting vs. a physician’s
office was varied by age. Time costs are always included for parents of children younger than 5 years of age assuming that a parent will need to be present for
vaccination of young children in any setting. See supporting information for additional details.
4For the physician office setting, the proportion of persons needing one vs. two extra physician visits to accommodate vaccination was varied by age. Time costs were
included for parents of children ,18 and for adults for each extra visit required for vaccination. For the physician office setting, we include 60 minutes of time for travel,
waiting, and vaccination time for either the vaccinee or the parent, which assumes a streamlined setting is used for vaccination.
doi:10.1371/journal.pone.0022308.t002
H1N1 Vaccination
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The primary health outcome for the analysis is the quality-
adjusted life year (QALY). A QALY attempts to measure a
patient’s physical health and well being including, among other
factors, the ability to engage in ‘‘normal,’’ everyday activities.
QALYs lost to a disease or condition, therefore, measure the
overall reduction in a patient’s well being, or health-related quality
of life, due to an episode of disease and its consequences (which
may last a life time). We obtained the loss in QALYs associated
with each influenza-related health event from published studies
and primary data.[35,36,37] In these studies, respondents were
asked how much of their own lifetime they would be willing to
trade in order to avoid a case of influenza-related illness or a
vaccination-related adverse event (i.e., a time-tradeoff valuation).
(Tables S1, S2)
Cost-effectiveness Analysis
The main endpoint for the study was the incremental cost-
effectiveness ratio (ICER) calculated by dividing the net costs by
the net health benefits (as measured via QALYs) for vaccination
compared to no vaccination. An intervention is defined as cost-
saving if the intervention decreases dollar costs and also results in
an increase in QALYs. An intervention is defined as cost-effective
if it results in an increase in both costs and QALYs and the
resulting ratio is less than a determined threshold.[38] The
primary analysis explored a range of values for pH1N1 illness rates
and vaccination costs due to uncertainty regarding the severity of
the pH1N1 influenza season and preferred vaccination settings. All
costs and health effects lasting more than 1 year were discounted
at 3% per year.
Considerable uncertainty exists regarding the most likely setting
for pH1N1 vaccination (i.e., mass vaccination clinics compared
with physician offices). Therefore the primary analysis includes a
mass vaccination setting, a physician office setting, and a ‘‘mid-
range’’ cost setting that assumes a proportion of individuals is
vaccinated in each setting. This proportion varies by age. The
primary analysis assumes that some individuals will receive
pH1N1 vaccination at an existing physician visit which would be
associated with lower administration costs. An existing visit is
defined as a visit previously-scheduled for a purpose other than
pH1N1 vaccination. In the sensitivity analysis, we include a more
conservative scenario in which all individuals are vaccinated in the
physician office setting and require a vaccine-specific visit.
Sensitivity analyses explored changes in key variables including
the number of doses required for vaccination, costs of vaccination,
vaccination-related adverse events, and influenza-related hospital-
ization rates. A sensitivity analysis explored the change in cost-
effectiveness ratios if only one dose were required for children
younger than 10 years. Some studies have suggested higher costs of
influenza vaccination in the physician office setting[39,40],
therefore, we also conducted a sensitivity analysis that assumed
higher administration costs. Due to concerns that swine influenza
vaccination in 1976–1977 may have been associated with Guillain-
Barre ´ syndrome, sensitivity analyses included varying the proba-
bility of Guillain-Barre ´ syndrome following vaccination over a
wide range of possible values, from rates that may occur with
seasonal influenza vaccine (1 per million) to rates observed with
1976 swine influenza vaccine (1 per 100,000).
The primary analysis assumed timely pH1N1 vaccination prior
to the start of the outbreak. A scenario analysis evaluated initiation
of vaccination after the start of a hypothetical influenza season.
Each week after the start of the season that vaccination was
initiated was assumed to reduce the protective effect of the vaccine
according to the expected distribution of cases over a hypothetical
16-week influenza season assuming peak at 9 weeks and 70% of
cases occur between weeks 7–10.(Table S3) [41]
Results
Assuming a 21% overall attack rate and assuming that persons
were fully vaccinated prior to the start of the outbreak, pH1N1
vaccination was cost-saving for all high-risk subgroups ages 6
months to 64 years. For low-risk subgroups 6 months to 64 years,
pH1N1 vaccination required a net investment for a return in
health benefits. The cost-effectiveness ratios for these subgroups
ranged from $5,000–$18,000/QALY depending on age and risk.
Cost-effectiveness ratios were least favorable for persons aged 65
years and older.(Table 3)
Assuming a higher overall attack rate of 30%, cost-effectiveness
ratios were less than $30,000/QALY for all age and risk groups for
the full range of vaccination costs. Vaccination remained cost-
saving for all high-risk subgroups. For lower attack rates, cost-
effectiveness results were less favorable. Assuming an attack rate
similar to that for an average influenza season (7.6%), vaccination
was no longer cost-saving for all high-risk subgroups.(Table 3)
Results were sensitive to changes in the number of doses
required for children, costs of vaccination, and timing of vaccine
delivery. Requiring only one vaccine dose for children resulted in
more favorable cost-effectiveness ratios compared to two doses.
(Table S4) Cost-effectiveness ratios were 72-89% lower for lower-
risk children and vaccination remained cost-saving for high-risk
children.(Table S4)
Higher vaccination costs were associated with less favorable
cost-effectiveness ratios for vaccination. If we assume that all
adults will receive vaccination in the physician office setting at a
vaccine-specific visit (our most conservative setting for vaccina-
tion costs), cost-effectiveness ratios become less favorable by 26–
44% for lower-risk individuals, but remained cost-saving for
higher-risk adults who were younger than 65 years of age.
Assuming the cost per dose to be twice that in the primary
analysis resulted in cost-effectiveness ratios up to 68% higher than
the primary analysis, but cost-effectiveness ratios remained below
$100,000/QALY. Higher administration costs in the physician
office setting would result in higher cost-effectiveness ratios (up to
18% higher); vaccination remained cost-saving for high-risk
subgroups.(Table S4)
Results were not sensitive to changes in the probability of
Guillain-Barre ´ syndrome following vaccination when varying the
probability up to 1 in 100,000. Results were also not sensitive to an
increase in hospitalization rates for high-risk individuals based on
emerging pH1N1 data; vaccination remained cost-saving for high
risk groups.
Timing of vaccination affects the cost-effectiveness of vaccina-
tion and depended on when vaccination occurred and if the age
group under consideration required one or two doses. For
subgroups requiring two doses and vaccination is not initiated
until the third week of the season, vaccination remains cost-saving
for high-risk children and cost-effectiveness ratios remain below
$10,000/QALY for lower-risk children assuming a hypothetical
16-week flu season and normalized epidemic curve of illness. If
vaccination is initiated beyond the tenth week into a hypothetical
16-week influenza season, the cost-effectiveness ratios become less
favorable for subgroups requiring two doses. If vaccination is
initiated beyond the fifteenth week, no vaccination becomes the
preferred strategy from an economic perspective. For age groups
requiring one dose, cost-effectiveness ratios increase markedly if
vaccination is initiated at the ninth or tenth week of the epidemic.
Results are similar for adults with the exception of individuals 65
H1N1 Vaccination
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1
Vaccination Costs
Age Group Mass Vaccination Setting Mid-Range
2 Physician Office Setting
3
a. 5% influenza illness attack rate
6–23 months, LR $37,896 - $54,182
2y ,L R $42,190 - $60,278
3–4 y, LR $55,321 - $78,481
5–11 y, LR $41,664 $57,471 $106,152
12–17 y, LR $26,049 $35,998 $65,804
18–49 y, LR $38,393 $40,825 $43,257
50–64 y, LR $113,660 $119,678 $123,690
$65 y, all $255,920 $245,729 $235,537
6–23 months, HR $3,515 $10,104 $10,104
2y ,H R $3,709 $10,668 $10,668
3–4 y, HR $440 $8,218 $8,218
5–11 y, HR Cost-saving $3,130 $20,852
12–17 y, HR Cost-saving Cost-saving $4,668
18–49 y, HR Cost-saving Cost-saving Cost-saving
50–64 y, HR $1,795 $3,357 $4,398
b. 7.6% influenza illness attack rate (comparable to average attack rate for seasonal influenza)
6–23 months, LR $22,374 - $33,339
2y ,L R $25,312 - $37,492
3–4 y, LR $33,892 - $49,486
5–11 y, LR $25,515 $36,419 $69,130
12–17 y, LR $14,859 $21,581 $41,475
18–49 y, LR $22,552 $24,163 $25,775
50–64 y, LR $69,691 $73,615 $76,230
$65 y, all $158,736 $152,171 $145,607
6–23 months, HR Cost-saving $1,589 $1,589
2 y, HR Cost-saving $1,820 $1,820
3–4 y, HR Cost-saving Cost-saving Cost-saving
5–11 y, HR Cost-saving Cost-saving $7,351
12–17 y, HR Cost-saving Cost-saving Cost-saving
18–49 y, HR Cost-saving Cost-saving Cost-saving
50–64 y, HR Cost-saving Cost-saving Cost-saving
c. 15% influenza illness attack rate
6–23 months, LR $7,702 $13,638 $13,638
2y ,L R $9,360 $15,954 $15,954
3–4 y, LR $13,637 $22,079 $22,079
5–11 y, LR $10,240 $16,207 $34,109
12–17 y, LR $4,275 $7,953 $18,989
18–49 y, LR $7,662 $8,502 $9,342
50–64 y, LR $28,976 $30,960 $32,282
$65 y, all $69,236 $66,011 $62,787
6–23 months, HR Cost-saving Cost-saving Cost-saving
2 y, HR Cost-saving Cost-saving Cost-saving
3–4 y, HR Cost-saving Cost-saving Cost-saving
5–11 y, HR Cost-saving Cost-saving Cost-saving
12–17 y, HR Cost-saving Cost-saving Cost-saving
18–49 y, HR Cost-saving Cost-saving Cost-saving
50–64 y, HR Cost-saving Cost-saving Cost-saving
d. 21% influenza illness attack rate
H1N1 Vaccination
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favorable.(Table 4)
Discussion
The Advisory Committee on Immunization Practices (ACIP)
recommended initial target groups for vaccination against pH1N1
influenza, which include pregnant women, household contacts of
infants younger than 6 months, health care and emergency
medical personnel, persons aged 6 months through 24 years, and
persons aged 25 through 64 years at higher risk for influenza-
related complications.[6] Using the assumptions from the primary
analysis, we find that the cost-effectiveness of vaccinating children
and high-risk working-age adults against pH1N1 is within the
range of cost-effectiveness for other vaccines recently recom-
mended by ACIP, including seasonal influenza vaccine[12],
pneumococcal conjugate vaccine[36], and HPV[42,43,44,45].
We also find that pH1N1 vaccination is cost-saving for high-risk
individuals less than 65 years under a wide range of assumptions.
We did not include separate analyses for some of the initial
target groups for recommendation, such as health care workers,
pregnant women, or household contacts of infants younger than 6
months. However, health care workers and pregnant women
would be included as part of the overall high-risk and low-risk
Vaccination Costs
Age Group Mass Vaccination Setting Mid-Range
2 Physician Office Setting
3
6–23 months, LR $1,053 $4,711 $4,711
2y ,L R $2,131 $6,194 $6,194
3–4 y, LR $4,459 $9,661 $9,661
5–11 y, LR $2,893 $6,486 $17,265
12–17 y, LR CS $1,399 $8,043
18–49 y, LR $2,115 $2,667 $3,220
50–64 y, LR $15,942 $17,305 $18,214
$65 y, all $42,901 $40,659 $38,417
6–23 months, HR Cost-saving Cost-saving Cost-saving
2 y, HR Cost-saving Cost-saving Cost-saving
3–4 y, HR Cost-saving Cost-saving Cost-saving
5–11 y, HR Cost-saving Cost-saving Cost-saving
12–17 y, HR Cost-saving Cost-saving Cost-saving
18–49 y, HR Cost-saving Cost-saving Cost-saving
50–64 y, HR Cost-saving Cost-saving Cost-saving
e. 30% influenza illness attack rate
6–23 months, LR $234 $3,611 $3,611
2y ,L R $1,240 $4,991 $4,991
3–4 y, LR $3,328 $8,130 $8,130
5–11 y, LR $2,495 $5,960 $16,352
12–17 y, LR Cost-saving $1,044 $7,450
18–49 y, LR $93 $541 $989
50–64 y, LR $8,528 $9,537 $10,211
$65 y, all $25,910 $24,302 $22,694
6–23 months, HR Cost-saving Cost-saving Cost-saving
2 y, HR Cost-saving Cost-saving Cost-saving
3–4 y, HR Cost-saving Cost-saving Cost-saving
5–11 y, HR Cost-saving Cost-saving Cost-saving
12–17 y, HR Cost-saving Cost-saving Cost-saving
18–49 y, HR Cost-saving Cost-saving Cost-saving
50–64 y, HR Cost-saving Cost-saving Cost-saving
LR = lower-risk; HR = higher-risk.
1Vaccination in each setting is compared to no vaccination.
2Assumes a mix of mass vaccination and physician office for individuals aged 5 years and older. For the mixed setting, the proportion of persons vaccinated in a mass
vaccination setting vs. a physician’s office was varied by age. For children younger than 5 years of age, the assumption is that very few children will be vaccinated in the
mass vaccination setting, therefore the physician office setting is considered to be the primary setting.
3For the physician office setting, the proportion of persons needing one vs. two extra physician visits to accommodate vaccination was varied by age. Time costs were
included for parents of children ,18 and for adults for each extra visit required for vaccination.
doi:10.1371/journal.pone.0022308.t003
Table 3. Cont.
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1, assuming 16-week influenza epidemic.
a. Age groups that require two doses (assumes 5 weeks to full protection; e.g., ‘‘Week 0’’ assumes that children are fully vaccinated prior to the first
week of the outbreak)
Week of Full
Immuniz-ation
2 6–23 m, HR 2 y, HR 3–4 y, HR 5–11 y, HR 6–23 m, LR 2 y, LR 3–4 y, LR 5–11 y, LR
0 C SC SC SC S$4,711 $6,194 $9,661 $6,486
1 C SC SC SC S$4,712 $6,195 $9,662 $6,487
2 C SC SC SC S$4,716 $6,199 $9,667 $6,490
3 C SC SC SC S$4,726 $6,210 $9,682 $6,501
4 C SC SC SC S$4,761 $6,248 $9,730 $6,537
5 C SC SC SC S$4,876 $6,374 $9,891 $6,656
6 C SC SC SC S$5,256 $6,790 $10,419 $7,045
7 C SC SC SC S$6,506 $8,156 $12,158 $8,329
8 C SC SC SC S$10,624 $12,658 $17,887 $12,556
9 C SC SC SC S$24,190 $27,489 $36,757 $26,482
10 $16,122 $16,921 $15,151 $8,635 $68,912 $76,383 $98,973 $72,398
11 $76,497 $79,656 $84,715 $64,147 $216,721 $237,985 $304,628 $224,209
12 $277,592 $288,617 $316,434 $249,119 $709,347 $776,645 $990,353 $730,798
13 $965,431 $1,003,421 $1,109,230 $882,681 $2,400,000 $2,638,889 $3,357,143 $2,474,642
14 $3,551,412 $3,691,592 $4,092,708 $3,276,700 $8,727,273 $10,555,556 $13,428,571 $9,200,000
15 $18,204,581 $18,948,070 $21,085,287 $17,213,376 $48,500,000 $95,000,000 $94,000,000 $46,000,000
16 NV NV NV NV NV NV NV NV
CS = Cost Saving; NV = No Vaccination is the preferred alternative as health risks of vaccination outweigh health benefits for these conditions.
b. Age groups that require one dose only (assumes that vaccination occurred 2 weeks prior to the ‘‘Week of Full Immunization’’
3)
Week of Full
Immuniz-ation
4 12–17 y, HR 18–49 y, HR 50–64 y, HR 12–17 y, LR 18–49 y, LR 50–64 y, LR $65 y, all
0 C SC SC S$1,399 $2,667 $17,305 $40,659
1 C SC SC S$1,400 $2,668 $17,037 $40,663
2 C SC SC S$1,402 $2,670 $17,314 $40,676
3 C SC SC S$1,409 $2,679 $17,337 $40,720
4 C SC SC S$1,433 $2,706 $17,411 $40,864
5 C SC SC S$1,513 $2,797 $17,654 $41,338
6 C SC SC S$1,776 $3,095 $18,456 $42,902
7 C SC SC S$2,641 $4,078 $21,099 $48,063
8 C SC SC S$5,491 $7,318 $29,836 $65,185
9 C SC SC S$14,881 $18,037 $58,951 $122,985
10 CS CS $13,120 $45,841 $53,880 $158,715 $330,107
11 $33,027 $21,073 $99,555 $148,216 $178,107 $536,073 $1,266,867
12 $156,273 $134,121 $423,416 $489,987 $668,719 $2,752,458 $71,159,030
13 $578,619 $586,517 $2,232,044 $1,668,217 $4,418,475 NV NV
14 $2,177,431 4,392,915 NV $6,500,000 NV NV NV
15 $11,577,092 NV NV $27,000,000 NV NV NV
16 NV NV NV NV NV NV NV
CS = Cost Saving; NV = No Vaccination is the preferred alternative as health risks of vaccination outweigh health benefits for these conditions.
LR = lower-risk; HR = higher-risk.
121% influenza illness attack rate, mid-range costs assumption.
2For children ,10 y needing two doses, vaccination would need to have been initiated $5 weeks earlier assuming 3 weeks between doses and 2 weeks after the
second dose for peak antibody response. http://www.cdc.gov/h1n1flu/vaccination/public/vaccination_qa_pub.htm For children $10 y, only one dose is needed.;
vaccination would need to have been initiated $2 weeks earlier for peak antibody response. Intermediate protection in between weeks 3 and 5 for children who have
received the first of two doses is conservatively assumed to be zero.
3Vaccination is assumed to require 2 weeks to achieve full protection.
4For individuals $10 y, only one dose is needed. Vaccination would need to have been initiated $2 weeks earlier for peak antibody response.
doi:10.1371/journal.pone.0022308.t004
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workers influenza and increased risk of complications of pH1N1 in
pregnant women[46], cost-effectiveness ratios would likely be at
least as favorable as for corresponding target groups as defined by
age and risk category.
The live attenuated formulation is not explicitly included in the
current analysis. Live attenuated vaccine for seasonal influenza
may be more effective than inactivated vaccine for young
children[47], yet recent data suggest that inactivated vaccines
may be more effective for young adults[48]. However, there are no
data on the effectiveness of live attenuated pH1N1 vaccine by age
group and it is possible that this may differ from that for seasonal
vaccine.
Emerging data on the epidemiology of pH1N1 influenza virus
infection were used in the simulation model where available, but
some assumptions were based on data from seasonal influenza.
These include the probability that an individual will seek medical
attention if they experience influenza-like illness. If individuals are
more likely to seek medical attention if they think they have
pH1N1 infection, these results represent a conservative approach
to assessing the cost-effectiveness of vaccination. Similarly, if the
costs of treating pH1N1 infection are substantially higher than for
seasonal influenza, the results of this analysis will also be
conservative. We did not consider any costs related to potential
school closures or mandated absences from school or work due to
illness. If these costs were appreciable, the results would be more
favorable for vaccination if these additional costs of illness were
included.
Policy Implications
This analysis differs from dynamic models, which model the
indirect effects of vaccination. One such model suggested that
vaccinating school-aged children and adults between the ages of
30 and 40 would be most cost-effective.[7] Dynamic models
simulate the transmission of infection among individuals and
estimate the reduction in infections as a result of reduced
transmission among unvaccinated age groups (e.g., vaccinating
school children will reduce transmission to individuals of other
ages and result in indirect effects of reducing illness and deaths in
infants and the elderly). The current analysis intentionally excludes
possible indirect effects of vaccination and restricts the primary
analysis to the costs and health benefits to the vaccinated
individual. Required coverage rates to generate herd effects for
pH1N1 are unknown and substantial uncertainty exists for the
required minimum coverage level for seasonal influen-
za[49,50,51]. Even if higher coverage rates are attained or
pH1N1 vaccination compared to seasonal influenza vaccination,
the effect of herd immunity is uncertain.[49,50,51] Another
rationale for restricting the analysis to individual-level benefits
relates to societal preferences. A policy of vaccinating school
children to prevent illness in other age groups assumes that public
preferences are consistent with trading off the health and well-
being of school-aged children (in the form of risk for vaccination-
related adverse events) to protect people in other age groups.
Evidence suggesting that societal preferences may be more
consistent with prioritizing child health over adult health could
clearly support the vaccination of children if the expected benefits
to the child outweighed the potential costs and risks but the
decision to vaccinate a child may only consider benefits and risks
to the vaccinated child.[37] Given that the inclusion of herd effects
would result in an increase in the health benefits associated with
vaccination, an extension of the current analysis to include herd
effects would result in more favorable cost-effectiveness results.
The costs of vaccination have a substantial impact on cost-
effectiveness results. Uncertainty exists as to the proportion of
individuals likely to get vaccinated in each type of setting. Since
costs of vaccination will vary with setting, these are key
assumptions for the analysis. For higher attack rate scenarios,
cost-effectiveness ratios vary about 10% across settings, however, if
most people are vaccinated in the physician office setting and
require a vaccine-specific visit, vaccination costs will be higher and
associated cost-effectiveness ratios will be less favorable. On the
other hand, if only one dose is required for vaccinating children,
the associated costs will be lower and cost-effectiveness ratios will
be more favorable. Recent data from the 2009–2010 pH1N1
vaccination season indicate that a mix of settings was used for
vaccination against pH1N1 influenza.[52] Results of sensitivity
analysis varying the costs of vaccination could provide useful
information for future decision making given the sensitivity of the
results to this input parameter.
Initiation of vaccination after the start of the season will affect
the cost-effectiveness of vaccination depending on the timing of
availability relative to the start, duration, and intensity of influenza
activity in a community. For children who require two doses,
vaccination may not be cost-effective if vaccine is delivered such
that full protection is not achieved until after the 8
th week (the
peak) of a hypothetical influenza season. For adults and children
requiring only one dose, results are similar but the timing of
vaccination required will differ since only one dose is assumed to
be required for full protection. Cost-effectiveness results would
differ if additional pandemic waves caused by a similar virus were
to occur within the same vaccination year, or if vaccination later
during a single pandemic wave provided some beneficial
immunologic priming for subsequent vaccination against a drifted
influenza virus, or if the pattern of disease during the pandemic
wave does not conform to our model of a hypothetical season.
Comparison to Other Economic Studies of pH1N1
Vaccination
Estimates of the economic impact of vaccination are available
for the US and other countries. In the US, Beigi et al. evaluate the
economic value of vaccinating pregnant women, a very high risk
group not included in our analysis, and report favorable cost-
effectiveness ratios for maternal influenza vaccination.[53] Kha-
zeni et al. (2009) evaluate the cost-effectiveness of vaccination
against pandemic influenza A (H1N1) for a major US metropol-
itan city and early vaccination to be cost-saving.[54] Lee et al.
(2010) estimate averted lost productivity costs for an employee
population but do not report results using an economic metric
such as an incremental cost-effectiveness ratio making it difficult to
compare these results with those from our study.[55] Sander et al
(2010) find the cost-effectiveness of a mass immunization program
for pandemic H1N1 to be favorable but this study does not
evaluate the cost-effectiveness of individual age and risk
groups.[56] Baguelin et al. (2010) use a dynamic model to
evaluate vaccination against pandemic influenza A(H1N1) in
England.[57] Our analysis complements other published analyses
both for the US and abroad by evaluating the cost-effectiveness of
individual age and risk groups and considering explicitly the effects
of delay in vaccination on cost-effectiveness. While it is difficult to
directly compare cost-effectiveness analyses across countries due to
differences in costs of services and level of intensity of care, results
from other countries were consistent with ours in estimating
favorable cost-effectiveness for mass vaccination in England and
Canada. Our analysis provides additional information to the
previously published studies by providing incremental cost-
effectiveness ratios for separate age and risk groups relevant to
H1N1 Vaccination
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relevant to the US decision maker perspective for costs of
vaccination, influenza illness rates, and delays in vaccination
using the best available information at the time of the pandemic.
None of the published studies reviewed above appear to have
accounted for costs or health consequences potentially associated
with H1N1 vaccination, except for the Khazeni et al and Beigi et
al. studies. The exclusion of vaccination-related adverse events
would yield more favorable results for vaccination compared with
a more comprehensive analysis that included adverse events. Both
costs and health effects of potential vaccine adverse events are
explicitly accounted for in our analysis. Additionally, outside the
US, adjuvanted vaccine was typically used and this formulation
could result in a different risk profile than non-adjuvanted vaccine.
The study by Khazeni et al. assumed the use of adjuvanted vaccine
for a US setting and is not directly comparable to our study due to
assumed differences in effectiveness and side effect profile between
the two formulations.
Conclusions
Vaccination for pH1N1 influenza for children and young adults
is cost-effective compared to other preventive health interventions
under a wide range of scenarios. Delayed availability of pH1N1
vaccine results in less favorable cost-effectiveness results. A
vaccination program for pH1N1 influenza for target groups can
be justified from an economic perspective when indirect benefits
are not considered and assuming that vaccine supplies are
sufficient. Additional economic and health benefits beyond direct
benefits would only add to the cost-effectiveness of pandemic
influenza vaccination.
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